Juan Alderuccio

Medicine & Life Sciences

1. Lymphoma 100%
2. Survival 58%
3. Lymphoma, Large B-Cell, Diffuse 51%
4. Follicular Lymphoma 44%
5. Burkitt Lymphoma 38%
6. Progression-Free Survival 36%
7. Mantle-Cell Lymphoma 27%
8. IVAM regimen 26%
9. Non-Hodgkin's Lymphoma 22%
10. Central Nervous System 21%
11. Survival Analysis 20%
12. Marginal Zone B-Cell Lymphoma 18%
13. HIV 17%
14. Rituximab 17%
15. Plasmablastic Lymphoma 17%
16. Bendamustine Hydrochloride 16%
17. Tumor Necrosis Factor Receptor-Associated Peptides and Proteins 15%
18. Drug Therapy 15%
19. B-Cell Lymphoma 13%
20. Germinal Center 13%
21. Methotrexate 12%
22. AIDS-Related Lymphoma 12%
23. Massage 12%
24. Lymphoproliferative Disorders 12%
25. Therapeutics 11%
26. Radiotherapy 11%
27. Epidemiology 11%
28. Human Herpesvirus 4 11%
29. Safety 11%
30. Hepatitis C 10%
31. Hematologic Neoplasms 10%
32. Observation 10%
33. Population 10%
34. Maintenance 10%
35. Tumor Burden 10%
36. Liver Transplantation 9%
37. Multicenter Studies 9%
38. Thyroid Gland 8%
39. Colon 8%
40. Mutation 8%
41. Breast 8%
42. Recurrence 7%
43. Cohort Studies 7%
44. Albumins 6%
45. Transplants 6%
46. Splenectomy 6%
47. Lung 6%
48. Neoplasms 6%
49. B-Lymphocytes 6%